TSS
AKBA icon

Two Sigma Securities’s Akebia Therapeutics AKBA Stock Holding History

Two Sigma Securities’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.8K Buy
+40,134
New +$47.8K ﹤0.01% 1396
2025
Q1 		– Sell
-40,826
Closed -$77.6K – 1424
2024
Q4 		$77.6K Buy
40,826
+27,517
+207% +$47.8K 0.01% 1137
2024
Q3 		$17.6K Buy
+13,309
New +$17.8K ﹤0.01% 2514
2024
Q2 		– Sell
-32,073
Closed -$58.7K – 2933
2024
Q1 		$58.7K Buy
32,073
+20,202
+170% +$32.3K ﹤0.01% 2549
2023
Q4 		$14.7K Sell
11,871
-5,032
-30% -$5.13K ﹤0.01% 2767
2023
Q3 		$19.3K Sell
16,903
-8,382
-33% -$10.8K ﹤0.01% 2577
2023
Q2 		$23.1K Sell
25,285
-112,752
-82% -$109K ﹤0.01% 2487
2023
Q1 		$77.4K Buy
138,037
+54,269
+65% +$41.5K ﹤0.01% 2231
2022
Q4 		$48.3K Buy
83,768
+57,634
+221% +$18.1K ﹤0.01% 2169
2022
Q3 		$8K Sell
26,134
-9,465
-27% -$3.71K ﹤0.01% 2426
2022
Q2 		$13K Buy
35,599
+3,430
+11% +$1.44K ﹤0.01% 2013
2022
Q1 		$23K Sell
32,169
-742
-2% -$1.59K ﹤0.01% 1958
2021
Q4 		$74K Buy
32,911
+11,550
+54% +$31.5K ﹤0.01% 1213
2021
Q3 		$62K Buy
+21,361
New +$61K ﹤0.01% 1361
2021
Q2 		– Sell
-14,046
Closed -$48K – 1477
2021
Q1 		$48K Buy
+14,046
New +$50.6K ﹤0.01% 737
2020
Q1 		– Sell
-30,694
Closed -$194K – 1310
2019
Q4 		$194K Buy
+30,694
New +$146K ﹤0.01% 2099
2019
Q1 		– Sell
-10,285
Closed -$57K – 1788
2018
Q4 		$57K Buy
+10,285
New +$80.5K ﹤0.01% 1923

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Securities's AKBA Position: Q2 2026 in Review

Two Sigma Securities opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 40,134 shares worth $45.8K. The stake represents ﹤0.01% of the portfolio and ranks #1396 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in AKBA as recently as Q4 2024.

Two Sigma Securities first reported a position in AKBA in Q4 2018 and has held it in 17 quarters since. The position peaked at $194K in Q4 2019. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Two Sigma Securities held 40,134 shares of Akebia Therapeutics worth $45.8K as of Q2 2026.
  • Akebia Therapeutics was a new Two Sigma Securities position in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Two Sigma Securities's portfolio in Q2 2026, its #1396 holding.
  • Two Sigma Securities first reported a position in Akebia Therapeutics in Q4 2018 and has held it in 17 quarters since.
  • Two Sigma Securities's Akebia Therapeutics position peaked at $194K in Q4 2019.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.